Zymeworks names new CEO

Zymeworks (NYSE:ZYME) will install Ken Galbraith as chairman and CEO, replacing the company’s outgoing leader Ali Tehrani on or before February 1. 

Galbraith has more than 30 years of experience working in life sciences, venture capital and global commercialization. 

“Ken Galbraith is an outstanding global leader who brings more than 30 years of life science

industry, venture capital and commercialization experience to Zymeworks, along with a proven track record of strong leadership and operational skills,” said Lota Zoth, Zymeworks’ current board chair, in a statement.

Tehrani has served as president and CEO since 2003. 

Ken Galbraith

The company also announced that it would give its chief financial officer (CFO) Neil Klompas chief operating officer duties. Klompas will also retain his CFO mantle. 

Specializing in multifunctional, antibody-based drugs, Zymeworks plans on r…

Read more
  • 0

Zymeworks and its partner BeiGene expand zanidatamab pivotal trial in Asia

Zymeworks (NYSE:ZYME) and its collaborator BeiGene have announced the dosing of the first patient with zanidatamab (ZW25) in South Korea–based HERIZON-GEA-01 study. The study will focus on patients with advanced or metastatic HER2-positive gastroesophageal adenocarcinomas.

As a result of the development, Zymeworks will receive an $8 million development milestone payment from BeiGene.

Zymeworks and BeiGene plan to open roughly 300 clinical trial sites in 38 countries for the global HERIZON-GEA-01 pivotal trial. The companies anticipate approximately 700 patients to enroll in the study.

The Phase 3 trial will evaluate zanidatamab with a physician’s choice of chemotherapy (capecitabine/oxaliplatin or 5FU/cisplatin) with or without the PD-1 inhibitor tislelizumab. The study will pit that cohort against a group receiving trastuzumab and a physician’s choice chemotherapy.

Zanidatamab, a bispecific antibody, is one of Zymeworks’ lead drug candidates.

Read more
  • 0